Edgewise Therapeutics, Inc. (EWTX) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Edgewise Therapeutics, Inc. (EWTX) posted $0 in revenue for fiscal 2025, with a net loss of $167.79M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. has grown revenue from $0 to $0 over the last 6 fiscal years.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Edgewise Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Edgewise Therapeutics, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-17.12M | $-42.81M | $-67.64M | $-100.16M | $-133.81M | $-167.79M |
| Net margin | — | — | — | — | — | — |
Source: Edgewise Therapeutics, Inc. SEC filings (10-K).
Edgewise Therapeutics, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 114.6% over 4 years (49.5M → 106.2M) — existing holders' stakes are being diluted.
Explore 6 years of Edgewise Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track EWTX in your portfolio →
Edgewise Therapeutics, Inc. financial history by metric
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Edgewise Therapeutics, Inc. — frequently asked questions
What is Edgewise Therapeutics, Inc.'s revenue?
Edgewise Therapeutics, Inc. (EWTX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Edgewise Therapeutics, Inc. profitable?
No — EWTX reported a net loss of $-167.79M in fiscal 2025.
What is EWTX's P/E ratio?
Edgewise Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Edgewise Therapeutics, Inc. have?
As of fiscal year 2025, EWTX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Edgewise Therapeutics, Inc.'s market cap?
Edgewise Therapeutics, Inc. (EWTX) has a market capitalization of about $3.65B, based on the latest data in our nightly-refreshed cache.
When does Edgewise Therapeutics, Inc.'s fiscal year end?
EWTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Edgewise Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.